Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis
Author:
Publisher
Elsevier BV
Subject
Neurology (clinical),Neurology,General Medicine
Reference33 articles.
1. Randomized trial of oral teriflunomide for relapsing multiple sclerosis;O'Connor;N. Engl. J. Med.,2011
2. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study;Kappos,2012
3. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro;Li;J. Neuroimmunol.,2013
4. Immune mechanisms of new therapeutic strategies in MS: teriflunomide;Claussen;Clin. Immunol.,2012
5. Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney: role of Tregs and stem cells;Baban;Am. J. Physiol. Regul. Integr. Comp. Physiol.,2012
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The ratio of circulating CD56dim NK cells to follicular T helper cells as a promising predictor for disease activity of relapsing-remitting multiple sclerosis;Heliyon;2024-05
2. Intruders or protectors – the multifaceted role of B cells in CNS disorders;Frontiers in Cellular Neuroscience;2024-01-10
3. Discovery a series of novel inhibitors of human dihydroorotate dehydrogenase: Biological activity evaluation and molecular docking;Chemical Biology & Drug Design;2023-11-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3